The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

In the world of consumer marketing, people-based data has become the gold standard. Demographics are just the starting point. Layered on top are deep behavioural insights into what people buy, browse, ...

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments, including GLP-1 agonist therapies. The shift from a ...

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...

It is in the shadow of these changes that the 7th Cell Therapy Analytical Development Summit returns to unite the field.

Six digital health technologies (DHTs) that can help with the rehabilitation of people with cardiovascular disease have been ...

Merck KGaA's recently acquired SpringWorks unit has claimed EU approval for Ogsiveo, becoming the first approved therapy for ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to tackle one or more of those areas. But what if an agency were to redesign ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...